Page 147«..1020..146147148149..160170..»

UNITY BIOTECHNOLOGY, INC. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,…

Posted: October 21, 2022 at 2:48 am

UNITY BIOTECHNOLOGY, INC. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-  Marketscreener.com

View post:
UNITY BIOTECHNOLOGY, INC. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,...

Posted in Biotechnology | Comments Off on UNITY BIOTECHNOLOGY, INC. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,…

Where Does Travere Therapeutics Inc (TVTX) Stock Fall in the Biotechnology Field After It Is Lower By -14.57% This Week? – InvestorsObserver

Posted: October 21, 2022 at 2:48 am

Where Does Travere Therapeutics Inc (TVTX) Stock Fall in the Biotechnology Field After It Is Lower By -14.57% This Week?  InvestorsObserver

Link:
Where Does Travere Therapeutics Inc (TVTX) Stock Fall in the Biotechnology Field After It Is Lower By -14.57% This Week? - InvestorsObserver

Posted in Biotechnology | Comments Off on Where Does Travere Therapeutics Inc (TVTX) Stock Fall in the Biotechnology Field After It Is Lower By -14.57% This Week? – InvestorsObserver

Gilead, working to improve cancer cell therapy, partners with California startup – BioPharma Dive

Posted: October 21, 2022 at 2:39 am

  1. Gilead, working to improve cancer cell therapy, partners with California startup  BioPharma Dive
  2. Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers  Gilead Sciences
  3. Kite Pharma Licenses Refuge Biotechnologies Platform to Bolster CAR T-Cell Therapy Development  Precision Oncology News
  4. Gilead's Kite ties itself to Refuge's gene platform in blood cancer CAR-T deal  FierceBiotech
  5. View Full Coverage on Google News

See the original post here:
Gilead, working to improve cancer cell therapy, partners with California startup - BioPharma Dive

Posted in Cell Therapy | Comments Off on Gilead, working to improve cancer cell therapy, partners with California startup – BioPharma Dive

Nano based drug delivery systems: recent developments and future …

Posted: October 21, 2022 at 2:37 am

Swamy MK, Sinniah UR. Patchouli (Pogostemon cablin Benth.): botany, agrotechnology and biotechnological aspects. Ind Crops Prod. 2016;87:16176.

Article CAS Google Scholar

Mohanty SK, Swamy MK, Sinniah UR, Anuradha M. Leptadenia reticulata (Retz.) Wight & Arn. (Jivanti): botanical, agronomical, phytochemical, pharmacological, and biotechnological aspects. Molecules. 1019;2017:22.

Google Scholar

Rodrigues T, Reker D, Schneider P, Schneider G. Counting on natural products for drug design. Nat Chem. 2016;8:531.

Article CAS PubMed Google Scholar

Siddiqui AA, Iram F, Siddiqui S, Sahu K. Role of natural products in drug discovery process. Int J Drug Dev Res. 2014;6(2):172204.

CAS Google Scholar

Beutler JA. Natural products as a foundation for drug discovery. Curr Prot Pharmacol. 2009;46(1):911.

Google Scholar

Thilakarathna SH, Rupasinghe H. Flavonoid bioavailability and attempts for bioavailability enhancement. Nutrients. 2013;5:336787.

Article PubMed PubMed Central CAS Google Scholar

Bonifcio BV, da Silva PB, dos Santos Ramos MA, Negri KMS, Bauab TM, Chorilli M. Nanotechnology-based drug delivery systems and herbal medicines: a review. Int J Nanomed. 2014;9:1.

Article CAS Google Scholar

Watkins R, Wu L, Zhang C, Davis RM, Xu B. Natural product-based nanomedicine: recent advances and issues. Int J Nanomed. 2015;10:6055.

CAS Google Scholar

Martinho N, Damg C, Reis CP. Recent advances in drug delivery systems. J Biomater Nanobiotechnol. 2011;2:510.

Article CAS Google Scholar

Jahangirian H, Lemraski EG, Webster TJ, Rafiee-Moghaddam R, Abdollahi Y. A review of drug delivery systems based on nanotechnology and green chemistry: green nanomedicine. Int J Nanomed. 2017;12:2957.

Article CAS Google Scholar

Liu Z, Tabakman S, Welsher K, Dai H. Carbon nanotubes in biology and medicine: in vitro and in vivo detection, imaging and drug delivery. Nano Res. 2009;2:85120.

Article CAS PubMed PubMed Central Google Scholar

Orive G, Gascon AR, Hernndez RM, Domnguez-Gil A, Pedraz JL. Techniques: new approaches to the delivery of biopharmaceuticals. Trends Pharmacol Sci. 2004;25:3827.

Article CAS PubMed Google Scholar

Razzacki SZ, Thwar PK, Yang M, Ugaz VM, Burns MA. Integrated microsystems for controlled drug delivery. Adv Drug Deliv Rev. 2004;56:18598.

Article PubMed CAS Google Scholar

Arayne MS, Sultana N, Qureshi F. nanoparticles in delivery of cardiovascular drugs. Pak J Pharm Sci. 2007;20:3408.

CAS PubMed Google Scholar

Patra JK, Baek K-H. Green nanobiotechnology: factors affecting synthesis and characterization techniques. J Nanomater. 2014;2014:219.

Article CAS Google Scholar

Joseph RR, Venkatraman SS. Drug delivery to the eye: what benefits do nanocarriers offer? Nanomedicine. 2017;12:683702.

Article CAS PubMed Google Scholar

Mirza AZ, Siddiqui FA. Nanomedicine and drug delivery: a mini review. Int Nano Lett. 2014;4:94.

Article CAS Google Scholar

Rudramurthy GR, Swamy MK, Sinniah UR, Ghasemzadeh A. Nanoparticles: alternatives against drug-resistant pathogenic microbes. Molecules. 2016;21:836.

Article CAS PubMed Central Google Scholar

Lam P-L, Wong W-Y, Bian Z, Chui C-H, Gambari R. Recent advances in green nanoparticulate systems for drug delivery: efficient delivery and safety concern. Nanomedicine. 2017;12:35785.

Article CAS PubMed Google Scholar

Haba Y, Kojima C, Harada A, Ura T, Horinaka H, Kono K. Preparation of poly (ethylene glycol)-modified poly (amido amine) dendrimers encapsulating gold nanoparticles and their heat-generating ability. Langmuir. 2007;23:52436.

Article CAS PubMed Google Scholar

Shi X, Sun K, Baker JR Jr. Spontaneous formation of functionalized dendrimer-stabilized gold nanoparticles. J Phys Chem C. 2008;112:82518.

Article CAS Google Scholar

Park S-H, Oh S-G, Mun J-Y, Han S-S. Loading of gold nanoparticles inside the DPPC bilayers of liposome and their effects on membrane fluidities. Coll Surf B. 2006;48:1128.

Article CAS Google Scholar

de Villiers MM, Aramwit P, Kwon GS. Nanotechnology in drug delivery. New York: Springer; 2008.

Google Scholar

Kabanov AV, Lemieux P, Vinogradov S, Alakhov V. Pluronic block copolymers: novel functional molecules for gene therapy. Adv Drug Deliv Rev. 2002;54:22333.

Article CAS PubMed Google Scholar

Wang N, Feng Y. Elaborating the role of natural products-induced autophagy in cancer treatment: achievements and artifacts in the state of the art. BioMed Res Int. 2015;2015:934207.

PubMed PubMed Central Google Scholar

Ouattara B, Simard RE, Holley RA. Piette GJ-P, Bgin A: Antibacterial activity of selected fatty acids and essential oils against six meat spoilage organisms. Int J Food Microbiol. 1997;37:15562.

Article CAS PubMed Google Scholar

Sharma G, Raturi K, Dang S, Gupta S, Gabrani R. Combinatorial antimicrobial effect of curcumin with selected phytochemicals on Staphylococcus epidermidis. J Asian Nat Prod Res. 2014;16:53541.

Article CAS PubMed Google Scholar

Abdelwahab SI, Sheikh BY, Taha MME, How CW, Abdullah R, Yagoub U, El-Sunousi R, Eid EE. Thymoquinone-loaded nanostructured lipid carriers: preparation, gastroprotection, in vitro toxicity, and pharmacokinetic properties after extravascular administration. Int J Nanomed. 2013;8:2163.

Article CAS Google Scholar

Krauel K, Pitaksuteepong T, Davies NM, Rades T. Entrapment of bioactive molecules in poly (alkylcyanoacrylate) nanoparticles. Am J Drug Deliv. 2004;2:2519.

Article CAS Google Scholar

Tan Q, Liu W, Guo C, Zhai G. Preparation and evaluation of quercetin-loaded lecithin-chitosan nanoparticles for topical delivery. Int J Nanomed. 2011;6:1621.

Article CAS Google Scholar

Sanna V, Roggio AM, Siliani S, Piccinini M, Marceddu S, Mariani A, Sechi M. Development of novel cationic chitosan-and anionic alginatecoated poly (d, l-lactide-co-glycolide) nanoparticles for controlled release and light protection of resveratrol. Int J Nanomed. 2012;7:5501.

CAS Google Scholar

Casettari L, Illum L. Chitosan in nasal delivery systems for therapeutic drugs. J Control Release. 2014;190:189200.

Article CAS PubMed Google Scholar

Obeid MA, Al Qaraghuli MM, Alsaadi M, Alzahrani AR, Niwasabutra K, Ferro VA. Delivering natural products and biotherapeutics to improve drug efficacy. Ther Deliv. 2017;8:94756.

Article CAS PubMed Google Scholar

Miele E, Spinelli GP, Miele E, Di Fabrizio E, Ferretti E, Tomao S, Gulino A. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomed. 2012;7:3637.

Google Scholar

McNamara K, Tofail SA. Nanosystems: the use of nanoalloys, metallic, bimetallic, and magnetic nanoparticles in biomedical applications. Phys Chem Chem Phys. 2015;17:2798195.

Article CAS PubMed Google Scholar

Saadeh Y, Vyas D. Nanorobotic applications in medicine: current proposals and designs. Am J Robot Surg. 2014;1:411.

Article PubMed PubMed Central Google Scholar

Oliveira ON Jr, Iost RM, Siqueira JR Jr, Crespilho FN, Caseli L. Nanomaterials for diagnosis: challenges and applications in smart devices based on molecular recognition. ACS Appl Mater Interfaces. 2014;6:1474566.

Article CAS PubMed Google Scholar

De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomed. 2008;3:133.

Article Google Scholar

Holzinger M, Le Goff A, Cosnier S. Nanomaterials for biosensing applications: a review. Front Chem. 2014;2:63.

Article PubMed PubMed Central CAS Google Scholar

Golovin YI, Gribanovsky SL, Golovin DY, Klyachko NL, Majouga AG, Master AM, Sokolsky M, Kabanov AV. Towards nanomedicines of the future: remote magneto-mechanical actuation of nanomedicines by alternating magnetic fields. J Control Release. 2015;219:4360.

Article CAS PubMed PubMed Central Google Scholar

Lu H, Wang J, Wang T, Zhong J, Bao Y, Hao H. Recent progress on nanostructures for drug delivery applications. J Nanomater. 2016;2016:20.

Google Scholar

Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941.

Article CAS PubMed PubMed Central Google Scholar

Kumari A, Kumar V, Yadav S. Nanotechnology: a tool to enhance therapeutic values of natural plant products. Trends Med Res. 2012;7:3442.

Article CAS Google Scholar

Chen F, Ehlerding EB, Cai W. Theranostic nanoparticles. J Nucl Med. 2014;55:191922.

Article CAS PubMed Google Scholar

Swierczewska M, Han H, Kim K, Park J, Lee S. Polysaccharide-based nanoparticles for theranostic nanomedicine. Adv Drug Deliv Rev. 2016;99:7084.

Article CAS PubMed Google Scholar

Chen K, Chen X. Design and development of molecular imaging probes. Curr Top Med Chem. 2010;10:122736.

Article CAS PubMed PubMed Central Google Scholar

Yhee JY, Son S, Kim SH, Park K, Choi K, Kwon IC. Self-assembled glycol chitosan nanoparticles for disease-specific theranostics. J Control Release. 2014;193:20213.

Article CAS PubMed Google Scholar

Lee C-M, Jang D, Kim J, Cheong S-J, Kim E-M, Jeong M-H, Kim S-H, Kim DW, Lim ST, Sohn M-H, et al. Oleyl-Chitosan nanoparticles based on a dual probe for Optical/MR imaging in vivo. Bioconjug Chem. 2011;22:18692.

Article CAS PubMed Google Scholar

Yang S-J, Lin F-H, Tsai H-M, Lin C-F, Chin H-C, Wong J-M, Shieh M-J. Alginate-folic acid-modified chitosan nanoparticles for photodynamic detection of intestinal neoplasms. Biomaterials. 2011;32:217482.

Article CAS PubMed Google Scholar

Ryu JH, Na JH, Ko HK, You DG, Park S, Jun E, Yeom HJ, Seo DH, Park JH, Jeong SY. Non-invasive optical imaging of cathepsin B with activatable fluorogenic nanoprobes in various metastatic models. Biomaterials. 2014;35:230211.

Article CAS PubMed Google Scholar

Read the original:
Nano based drug delivery systems: recent developments and future ...

Posted in Nano medicine | Comments Off on Nano based drug delivery systems: recent developments and future …

Automated Cell Culture Systems Market Size to Hit USD 12.43 Billion by 2033; Growing Stem Cell Research & Development and Increasing Prevalence of…

Posted: October 21, 2022 at 2:36 am

Automated Cell Culture Systems Market Size to Hit USD 12.43 Billion by 2033; Growing Stem Cell Research & Development and Increasing Prevalence of Non-Communicable Diseases to Elevate Market Growth Research Nester  GlobeNewswire

Read more:
Automated Cell Culture Systems Market Size to Hit USD 12.43 Billion by 2033; Growing Stem Cell Research & Development and Increasing Prevalence of...

Posted in Stem Cell Research | Comments Off on Automated Cell Culture Systems Market Size to Hit USD 12.43 Billion by 2033; Growing Stem Cell Research & Development and Increasing Prevalence of…

Global Stem Cell Umbilical Cord Blood (UCB) Market Report 2022-2026: Increased Federal Investment in Stem Cell Therapy, and the Advent of Cord Blood…

Posted: October 21, 2022 at 2:35 am

Global Stem Cell Umbilical Cord Blood (UCB) Market Report 2022-2026: Increased Federal Investment in Stem Cell Therapy, and the Advent of Cord Blood Banking to Drive Sector - ResearchAndMarkets.com  Business Wire

More:
Global Stem Cell Umbilical Cord Blood (UCB) Market Report 2022-2026: Increased Federal Investment in Stem Cell Therapy, and the Advent of Cord Blood...

Posted in Stem Cell Therapy | Comments Off on Global Stem Cell Umbilical Cord Blood (UCB) Market Report 2022-2026: Increased Federal Investment in Stem Cell Therapy, and the Advent of Cord Blood…

Global Cell Culture Protein Surface Coating Market to Grow at a CAGR of 13.82% During 2022-2031; Market to Expand on the Back of the Technological…

Posted: October 21, 2022 at 2:35 am

Global Cell Culture Protein Surface Coating Market to Grow at a CAGR of 13.82% During 2022-2031; Market to Expand on the Back of the Technological Breakthrough in Stem Cell Transplantation and Gene Therapy Kenneth Research  GlobeNewswire

Read more:
Global Cell Culture Protein Surface Coating Market to Grow at a CAGR of 13.82% During 2022-2031; Market to Expand on the Back of the Technological...

Posted in Stem Cell Therapy | Comments Off on Global Cell Culture Protein Surface Coating Market to Grow at a CAGR of 13.82% During 2022-2031; Market to Expand on the Back of the Technological…

Brush Up: Tissue Engineering and Regenerative Medicine – The Scientist

Posted: October 21, 2022 at 2:27 am

  1. Brush Up: Tissue Engineering and Regenerative Medicine  The Scientist
  2. Top 3 grants in regenerative medicine: August 2022  RegMedNet
  3. Regenerative Medicine is Predicted to Grow at CAGR of 21.2% During the Forecast Period | Leading Players: 3M,  openPR
  4. Regenerative Medicine Market Is Anticipated To Grow At A Near 8.8% CAGR  Taiwan News
  5. Global Regenerative Medicine Market Size And Forecast | Organogenesis Inc., Osiris Therapeutics Vericel Corporation, Stryker Corporation and NuVasive, Inc. Sioux City Catholic Globe  Sioux City Catholic Globe
  6. View Full Coverage on Google News

Follow this link:
Brush Up: Tissue Engineering and Regenerative Medicine - The Scientist

Posted in Regenerative Medicine | Comments Off on Brush Up: Tissue Engineering and Regenerative Medicine – The Scientist

Embryonic Stem Cell Fact Sheet – University of WisconsinMadison

Posted: October 21, 2022 at 2:26 am

What are embryonic stem cells? All embryonic stem cells are undifferentiated cells that are unlike any specific adult cell. However, they have the ability to form any adult cell. Because undifferentiated embryonic stem cells can proliferate indefinitely in culture, they could potentially provide an unlimited source of specific, clinically important adult cells such as bone, muscle, liver or blood cells.

Where do embryonic stem cells come from? Human embryonic stem cells are derived from in vitro fertilized embryos less than a week old. These embryos were produced for clinical purposes, but were no longer wanted for implantation by the couples who donated them. They were donated specially for this project with the informed consent of donors. In virtually every in vitro fertilization clinic in the world, surplus embryos are discarded if they are not donated to help other infertile couples or for research. The research protocols were reviewed and approved by a UWMadison Institutional Review Board, a panel of scientists and medical ethicists who oversee such work.

Why are they important? Embryonic stem cells are of great interest to medicine and science because of their ability to develop into virtually any other cell made by the human body. In theory, if stem cells can be grown and their development directed in culture, it would be possible to grow cells of medical importance such as bone marrow, neural tissue or muscle.

What, precisely, has the UW team accomplished? Scientists have been attempting to isolate and culture human embryonic stem cells for more than a decade. Using 14 blastocysts obtained from donated, surplus embryos produced by in vitro fertilization, the Wisconsin group established five independent cell lines. The cell lines, derived from preimplantation stage embryos, were capable of prolonged, undifferentiated proliferation in culture and yet maintained the ability to develop into a variety of specific cell types, including neural, gut, muscle, bone and cartilage cells.

How might they be used to treat disease? The ability to grow human tissue of all kinds opens the door to treating a range of cell-based diseases and to growing medically important tissues that can be used for transplantation purposes. For example, diseases like juvenile onset diabetes mellitus and Parkinsons disease occur because of defects in one of just a few cells types. Replacing faulty cells with healthy ones offers hope of lifelong treatment. Similarly, failing hearts and other organs, in theory, could be shored up by injecting healthy cells to replace damaged or diseased cells.

Are there other potential uses for these cells? The first potential applications of human embryonic stem cell technology may be in the area of drug discovery. The ability to grow pure populations of specific cell types offers a proving ground for chemical compounds that may have medical importance. Treating specific cell types with chemicals and measuring their response offers a short-cut to sort out chemicals that can be used to treat the diseases that involve those specific cell types. Ramped up stem cell technology would permit the rapid screening of hundreds of thousands of chemicals that must now be tested through much more time-consuming processes.

What can these cells tell us about development? The earliest stages of human development have been difficult or impossible to study. Human embryonic stem cells will offer insights into developmental events that cannot be studied directly in humans in utero or fully understood through the use of animal models. Understanding the events that occur at the first stages of development has potential clinical significance for preventing or treating birth defects, infertility and pregnancy loss. A thorough knowledge of normal development could ultimately allow the prevention or treatment of abnormal human development. For instance, screening drugs by testing them on cultured human embryonic stem cells could help reduce the risk of drug-related birth defects.

If a cluster of these cells was transferred to a woman, could a pregnancy result? No. These cells are not the equivalent of an intact embryo. If a cluster of these cells was transferred to a uterus, they would fail to implant, and would fail to develop into a fetus.

Is stem cell research the same as cloning?No. Stem cell research aims to develop new life-saving treatments, and cannot be used to develop a human being. Embryonic stem cells derived from the inner cell mass of an early-stage embryo cannot give rise to a placenta, so a human being could not develop, even if the stem cells were implanted into a womans uterus.

Why not derive stem cells from adults?There are several approaches now in human clinical trials that utilize mature stem cells (such as blood-forming cells, neuron-forming cells and cartilage-forming cells). However, because adult cells are already specialized, their potential to regenerate damaged tissue is very limited: skin cells will only become skin and cartilage cells will only become cartilage. Adults do not have stem cells in many vital organs, so when those tissues are damaged, scar tissue develops. Only embryonic stem cells, which have the capacity to become any kind of human tissue, have the potential to repair vital organs.

Studies of adult stem cells are important and will provide valuable insights into the use of stem cell in transplantation procedures. However, only through exploration of all types of stem cell research will scientists find the most efficient and effective ways to treat diseases.

What are the benefits of studying stem cells?Pluripotent stem cells represent hope for millions of Americans. They have the potential to treat or cure a myriad of diseases, including Parkinsons, Alzheimers, diabetes, heart disease, stroke, spinal cord injuries and burns.

This extraordinary research is still in its infancy and practical application will only be possible with additional study. Scientists need to understand what leads cells to specialization in order to direct cells to become particular types of tissue. For example, islet cells control insulin production in the pancreas, which is disrupted in people with diabetes. If an individual with diabetes is to be cured, the stem cells used for treatment must develop into new insulin-producing islet cells, not heart tissue or other cells. Research is required to determine how to control the differentiation of stem cells so they will be therapeutically effective. Research is also necessary to study the potential of immune rejection of the Cells, and how to overcome that problem.

More:
Embryonic Stem Cell Fact Sheet - University of WisconsinMadison

Posted in Wisconsin Stem Cells | Comments Off on Embryonic Stem Cell Fact Sheet – University of WisconsinMadison

Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8

Posted: October 21, 2022 at 2:22 am

Conference call to begin at 4:30 p.m. ET

View post:
Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8

Posted in Global News Feed | Comments Off on Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8

Page 147«..1020..146147148149..160170..»